Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Peringkat dalam Saham #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Harga Saham
$22.26
Terakhir disinkronkan: 2024-03-22
Kapitalisasi Pasar
$553.40M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Graphite Bio, Inc. (GRPH)

Kategori

Riwayat dividen untuk Graphite Bio, Inc. (GRPH)
Saham Graphite Bio, Inc. (simbol: GRPH) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Graphite Bio, Inc. (GRPH) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
0.00%
US
0.00%
NL
64.00%
AU
0.00%
US
0.00%
CH